Abstract
BackgroundCheckpoint blockade immunotherapies have revolutionized cancer treatment, yet only a subset of patients benefit. Individuals with a loss-of-function single nucleotide polymorphism in the gene encoding PTPN22 are at increased risk...
Published Version (
Free)
Join us for a 30 min session where you can share your feedback and ask us any queries you have